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Background:  Despite the length of time HIV has been wreaking havoc on its victims, 
improvements in the prevention and treatment of HIV are needed.  Anti-retroviral therapy can be 
effective but is expensive and not entirely accessible for people infected in third world countries. 
Several promising broadly neutralizing antibodies have been isolated from infected individuals; 
we propose that generating antigen specific human monoclonal antibodies using humanized 
mice further represents a promising approach to engineer prophylactic antibodies to reduce 
spread and infection of HIV.   
 
Methods: Immunodeficient mice were engrafted with fetal liver and thymus (BLT) prior to 
infection with different HIV isolates.  HIV infection of the mice was monitored by viral load and 
antibody response followed by ELISA using gp120, gp41 or gp120/CD4 complex as antigens.  
Approximately 8-12 weeks post infection, spleens were harvested and splenocytes fused with 
human fusion partner HMMA 2.5 to isolate antibody-expressing hybridomas. Lead clones were 
scaled and purified for testing in functional assays such as TZM-bl neutralization assays as well 
as ADCVI to determine  neutralizing and cytotoxic ability of the antibodies. Antibody sequences 
were also determined for analysis. 
 
Results: A robust, specific antibody response, of both IgG and IgA isotypes, was generated in 
response to HIV infection.  Over 60 hybridomas were created that were not only 
immunoreactive with env antigens, but also had neutralization activity.  Moreover, variable 
family usage was not limited and somatic mutation was clearly evident. 
 
Conclusions: These findings suggest that humanized BLT mice are a novel source for well-
characterized, stable human monoclonal antibodies to HIV.   
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